Cargando…

Integrated network pharmacology and hepatic metabolomics to reveal the mechanism of Acanthopanax senticosus against major depressive disorder

Objective: Acanthopanax senticosus (Rupr. et Maxim.) Harms (ASH) is a traditional herbal medicine widely known for its antifatigue and antistress effects, as well as tonifying qi, invigorating spleen and kidney, and tranquilizing the mind. Recent evidence suggests that ASH has a therapeutic effect o...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Xinyi, Zhang, Guanying, Wang, Qixue, Song, Jing, Li, Ying, Xia, Chenyi, Zhang, Ting, Yang, Li, Sun, Jijia, Zhou, Mingmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389016/
https://www.ncbi.nlm.nih.gov/pubmed/35990602
http://dx.doi.org/10.3389/fcell.2022.900637
_version_ 1784770344573206528
author Gu, Xinyi
Zhang, Guanying
Wang, Qixue
Song, Jing
Li, Ying
Xia, Chenyi
Zhang, Ting
Yang, Li
Sun, Jijia
Zhou, Mingmei
author_facet Gu, Xinyi
Zhang, Guanying
Wang, Qixue
Song, Jing
Li, Ying
Xia, Chenyi
Zhang, Ting
Yang, Li
Sun, Jijia
Zhou, Mingmei
author_sort Gu, Xinyi
collection PubMed
description Objective: Acanthopanax senticosus (Rupr. et Maxim.) Harms (ASH) is a traditional herbal medicine widely known for its antifatigue and antistress effects, as well as tonifying qi, invigorating spleen and kidney, and tranquilizing the mind. Recent evidence suggests that ASH has a therapeutic effect on major depressive disorder (MDD), but its mechanism is still unclear. The current study aimed to investigate the effect of ASH on MDD and potential therapeutic mechanisms. Materials and Methods: The chemical compound potential target network was predicted based on network pharmacology. Simultaneously, chronic unpredictable mild stress (CUMS) model mice were orally administrated ASH with three dosages (400, 200, and 100 mg/kg) for 6 weeks, and hepatic metabolomics based on gas chromatography–mass spectrometry (GC–MS) was carried out to identify differential metabolites and related metabolic pathways. Next, the integrated analysis of metabolomics and network pharmacology was applied to find the key target. Finally, molecular docking technology was employed to define the combination of the key target and the corresponding compounds. Results: A total of 13 metabolites and four related metabolic pathways were found in metabolomics analysis. From the combined analysis of network pharmacology and metabolomics, six targets (DAO, MAOA, MAOB, GAA, HK1, and PYGM) are the overlapping targets and two metabolic pathways (glycine, serine, and threonine metabolism and starch and sucrose metabolism) are the most related pathways. Finally, DAO, MAOA, MAOB, GAA, HK1, and PYGM were verified bounding well to their corresponding compounds including isofraxidin, eleutheroside B1, eleutheroside C, quercetin, kaempferol, and acacetin. Conclusion: Based on these results, it was implied that the potential mechanism of ASH on MDD was related to the regulation of metabolism of several excitatory amino acids and carbohydrates, as well as the expression of DAO, MAOA, MAOB, GAA, HK1, and PYGM.
format Online
Article
Text
id pubmed-9389016
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93890162022-08-20 Integrated network pharmacology and hepatic metabolomics to reveal the mechanism of Acanthopanax senticosus against major depressive disorder Gu, Xinyi Zhang, Guanying Wang, Qixue Song, Jing Li, Ying Xia, Chenyi Zhang, Ting Yang, Li Sun, Jijia Zhou, Mingmei Front Cell Dev Biol Cell and Developmental Biology Objective: Acanthopanax senticosus (Rupr. et Maxim.) Harms (ASH) is a traditional herbal medicine widely known for its antifatigue and antistress effects, as well as tonifying qi, invigorating spleen and kidney, and tranquilizing the mind. Recent evidence suggests that ASH has a therapeutic effect on major depressive disorder (MDD), but its mechanism is still unclear. The current study aimed to investigate the effect of ASH on MDD and potential therapeutic mechanisms. Materials and Methods: The chemical compound potential target network was predicted based on network pharmacology. Simultaneously, chronic unpredictable mild stress (CUMS) model mice were orally administrated ASH with three dosages (400, 200, and 100 mg/kg) for 6 weeks, and hepatic metabolomics based on gas chromatography–mass spectrometry (GC–MS) was carried out to identify differential metabolites and related metabolic pathways. Next, the integrated analysis of metabolomics and network pharmacology was applied to find the key target. Finally, molecular docking technology was employed to define the combination of the key target and the corresponding compounds. Results: A total of 13 metabolites and four related metabolic pathways were found in metabolomics analysis. From the combined analysis of network pharmacology and metabolomics, six targets (DAO, MAOA, MAOB, GAA, HK1, and PYGM) are the overlapping targets and two metabolic pathways (glycine, serine, and threonine metabolism and starch and sucrose metabolism) are the most related pathways. Finally, DAO, MAOA, MAOB, GAA, HK1, and PYGM were verified bounding well to their corresponding compounds including isofraxidin, eleutheroside B1, eleutheroside C, quercetin, kaempferol, and acacetin. Conclusion: Based on these results, it was implied that the potential mechanism of ASH on MDD was related to the regulation of metabolism of several excitatory amino acids and carbohydrates, as well as the expression of DAO, MAOA, MAOB, GAA, HK1, and PYGM. Frontiers Media S.A. 2022-08-05 /pmc/articles/PMC9389016/ /pubmed/35990602 http://dx.doi.org/10.3389/fcell.2022.900637 Text en Copyright © 2022 Gu, Zhang, Wang, Song, Li, Xia, Zhang, Yang, Sun and Zhou. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cell and Developmental Biology
Gu, Xinyi
Zhang, Guanying
Wang, Qixue
Song, Jing
Li, Ying
Xia, Chenyi
Zhang, Ting
Yang, Li
Sun, Jijia
Zhou, Mingmei
Integrated network pharmacology and hepatic metabolomics to reveal the mechanism of Acanthopanax senticosus against major depressive disorder
title Integrated network pharmacology and hepatic metabolomics to reveal the mechanism of Acanthopanax senticosus against major depressive disorder
title_full Integrated network pharmacology and hepatic metabolomics to reveal the mechanism of Acanthopanax senticosus against major depressive disorder
title_fullStr Integrated network pharmacology and hepatic metabolomics to reveal the mechanism of Acanthopanax senticosus against major depressive disorder
title_full_unstemmed Integrated network pharmacology and hepatic metabolomics to reveal the mechanism of Acanthopanax senticosus against major depressive disorder
title_short Integrated network pharmacology and hepatic metabolomics to reveal the mechanism of Acanthopanax senticosus against major depressive disorder
title_sort integrated network pharmacology and hepatic metabolomics to reveal the mechanism of acanthopanax senticosus against major depressive disorder
topic Cell and Developmental Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389016/
https://www.ncbi.nlm.nih.gov/pubmed/35990602
http://dx.doi.org/10.3389/fcell.2022.900637
work_keys_str_mv AT guxinyi integratednetworkpharmacologyandhepaticmetabolomicstorevealthemechanismofacanthopanaxsenticosusagainstmajordepressivedisorder
AT zhangguanying integratednetworkpharmacologyandhepaticmetabolomicstorevealthemechanismofacanthopanaxsenticosusagainstmajordepressivedisorder
AT wangqixue integratednetworkpharmacologyandhepaticmetabolomicstorevealthemechanismofacanthopanaxsenticosusagainstmajordepressivedisorder
AT songjing integratednetworkpharmacologyandhepaticmetabolomicstorevealthemechanismofacanthopanaxsenticosusagainstmajordepressivedisorder
AT liying integratednetworkpharmacologyandhepaticmetabolomicstorevealthemechanismofacanthopanaxsenticosusagainstmajordepressivedisorder
AT xiachenyi integratednetworkpharmacologyandhepaticmetabolomicstorevealthemechanismofacanthopanaxsenticosusagainstmajordepressivedisorder
AT zhangting integratednetworkpharmacologyandhepaticmetabolomicstorevealthemechanismofacanthopanaxsenticosusagainstmajordepressivedisorder
AT yangli integratednetworkpharmacologyandhepaticmetabolomicstorevealthemechanismofacanthopanaxsenticosusagainstmajordepressivedisorder
AT sunjijia integratednetworkpharmacologyandhepaticmetabolomicstorevealthemechanismofacanthopanaxsenticosusagainstmajordepressivedisorder
AT zhoumingmei integratednetworkpharmacologyandhepaticmetabolomicstorevealthemechanismofacanthopanaxsenticosusagainstmajordepressivedisorder